+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 49Years
All Genders
Healthy Volunteers
ID07794748

Evaluating Safety and Immune Response of Three Lots of a New Multivalent Pneumococcal Conjugate Vaccine Compared to 20vPnC in Adults 18 to 49 Years

Led by Pfizer · Updated on 2026-10-14

4670

Participants Needed

37

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and immune response of a new multivalent pneumococcal conjugate vaccine called PG4 in adults aged 18 to 49 years. The study compares three different production lots of the PG4 vaccine to each other and to an existing 20-valent pneumococcal conjugate vaccine 20vPnC to confirm consistent vaccine performance and safety. Participants are randomly assigned to one of four groups three groups receive one of the three different lots of the PG4 vaccine, and the fourth group receives the 20vPnC vaccine. Each participant receives a single injection of their assigned vaccine in the arm. The study uses a randomized, double-blind design with groups allocated in a 2221 ratio to ensure balanced comparison. During the approximately six-month study participation, blood samples are collected to measure immune responses and monitor safety. Researchers assess local and systemic reactions within one week after vaccination, adverse events up to one month, and serious adverse events up to six months. They also analyze specific antibody levels and immune activity to evaluate how the vaccines stimulate the bodys defenses against pneumococcal disease.

CONDITIONS

Brief Title

A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults

Research Team

P

Pfizer CT.gov Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here